CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement
This article was originally published in The Pink Sheet Daily
Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.
You may also be interested in...
CNS candidates range from new mechanisms in multiple sclerosis to the first orexin antagonist for insomnia and refinements in neurotransmitter targeting for schizophrenia and depression. A second amyloid imaging agent could reach the market to aid in diagnosis of Alzheimer’s disease.
FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease offers options for trial design, but without biomarkers to accurately diagnose the disease and track its progression, a trial could be doomed from the start.
Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.